Dachaigh › Siondròman Myelodysplastic › Washington › Seattle
Sgrùdaidhean clionaigeach Siondròman Myelodysplastic ann an Seattle, WA
Tha 21 sgrùdaidhean airson Siondròman Myelodysplastic a’ lorg phàirtichean aig làraichean ann agus timcheall air Seattle (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
A’ fastadhÌre 2
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-First Hill, Seattle
- University of Washington Medical Center - Montlake, Seattle
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
A’ fastadhÌre 2
- Swedish Medical Center-First Hill, Seattle
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
A’ fastadhÌre 1
- Fred Hutchinson Cancer Center, Seattle
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
A’ fastadhÌre 1/2
- University of Washington, Seattle
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
A’ fastadhÌre 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
A’ fastadhÌre 1
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Collection of Tissue Samples for Cancer Research
A’ fastadhSgrùdadh amharc
- Fred Hutchinson, Seattle
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
A’ fastadhÌre 1/2
- Seattle Children's Hospital, Seattle
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
A’ fastadhÌre 2
- Fred Hutchinson Cancer Center, Seattle
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
A’ fastadhÌre 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
A’ fastadhÌre 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
A’ fastadhÌre 2Fàilte do shaor-thoilich fhallain
- Fred Hutch/University of Washington Cancer Consortium, Seattle
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
A’ fastadhÌre 1
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
A’ fastadhÌre 1/2Fàilte do shaor-thoilich fhallain
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
A’ fastadhÌre 2/3
- Seattle Cancer Care Alliance, Seattle
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
A’ fastadhÌre 1/2
- Fred Hutchinson Cancer Center, Seattle
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
A’ fastadhÌre 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
A’ fastadhÌre 2
- Fred Hutchinson Cancer Research Center, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
A’ fastadhSgrùdadh amharc
- Massive Bio SYNERGY-AI site, Seattle
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
A’ fastadhÌre 1
- Fred Hutchinson Cancer Center, Seattle
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
A’ fastadhÌre 1
- Fred Hutchinson Cancer Center, Seattle
Sgrùdaidhean Siondròman Myelodysplastic ann am bailtean eile
- Houston, TX43 sgrùdaidhean
- Baldwin Park, CA26 sgrùdaidhean
- New York City, NY21 sgrùdaidhean
- Washington, DC20 sgrùdaidhean
- Tampa, FL19 sgrùdaidhean
- Boston, MA19 sgrùdaidhean
- Miami, FL17 sgrùdaidhean
- Durham, NC14 sgrùdaidhean
- Columbus, OH14 sgrùdaidhean
- St. Louis, MO13 sgrùdaidhean
- Atlanta, GA13 sgrùdaidhean
- Chicago, IL13 sgrùdaidhean
Sgrùdaidhean eile ann an Seattle
- Aillse Sgamhain Neo-chealla-beag53 sgrùdaidhean
- Aillse (gach seòrsa)49 sgrùdaidhean
- Aillse Prostata42 sgrùdaidhean
- Leukemia myeloid geur41 sgrùdaidhean
- Aillse a' bhroilleach39 sgrùdaidhean
- Ailse metastatach39 sgrùdaidhean
- Aillse colorectal34 sgrùdaidhean
- Ailseachadh nan Sgamhan33 sgrùdaidhean
- Cancer Ovarian30 sgrùdaidhean
- Myeloma iomaill22 sgrùdaidhean
- Aillse sa bhlaire21 sgrùdaidhean
- Leukemia lymphoblastic geur21 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.